<DOC>
	<DOCNO>NCT02591914</DOCNO>
	<brief_summary>The objective study establish safety tolerability intravitreous administration alter regimen Fovista™ ( Anti-PDGF-B pegylated aptamer ) administer combination Anti-VEGF therapy ( Lucentis® , Avastin® Eylea® ) subject subfoveal neovascular age-related macular degeneration . Subjects treat Fovista™ Anti-VEGF therapy every month first three month . Retreatment Fovista™ Anti-VEGF occur follow finding present PER INVESTIGATOR DISCRETION : - ≥ 5 ETDRS letter loss OR ; - Significant hemorrhage OR ; - New increase RPE elevation consistent increase disease activity OR ; - Increased neovascular lesion size OR ; - New increase foveal intraretinal fluid If anti-VEGF re-treatment administer base re-treatment criterion note , Fovista™ anti-PDGF therapy MUST administer minimum every 3 month ( monotherapy ) . Therefore , subject treat Fovista™ Anti-VEGF therapy total 3-24 administration .</brief_summary>
	<brief_title>An Open-Label Investigator Sponsored Trial Investigate Safety , Tolerability Development Subfoveal Fibrosis By Intravitreal Administration Altering Regimens Fovista Anti-VEGF Therapy Subjects With Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Active subfoveal choroidal neovascularization ( CNV ) due AMD . Best correct visual acuity study eye 20/40 20/400 , inclusive . The VA must reconfirm Day 1 prior randomization . Active CNV must compromise least 25 % lesion measure fluorescein angiogram ( include blood , neovascularization , scar/atrophy ) Presence OCT subretinal hyperreflective material ( SHRM ) within central 1 mm subfield ; SHRM define hyperreflective material locate external outer retina internal RPE , , RPE well define , internal Bruch 's membrane . Clear ocular medium adequate pupillary dilatation allow collection fundus photograph fluorescein angiograms sufficient quality Subjects either gender age ≥ 50 year . Women must agree use two form effective contraception , postmenopausal least 12 month prior trial entry , surgically sterile ; childbearing potential , serum pregnancy test must perform within 14 day prior first injection negative result . The two form effective contraception must implement trial least 60 day follow last dose test medication . Provide write informed consent . Ability comply study followup procedure return trial visit . More 50 % total lesion size make scar atrophy determine fundus photography without fluorescein angiography , without OCT . Subjects subfoveal scar subfoveal atrophy directly center fovea exclude . More 50 % total lesion size consist subretinal hemorrhage . Presence retinal angiomatous proliferation ( RAP ) . Presence significant serous pigment epithelial detachment ( PEDs ) , large PEDs constitute great 50 % total lesion vertical height ≥ 400 µm . Presence pure PED without subretinal hyperreflective material . Presence pigment epithelial tear rip . Presence intraocular inflammation ( ≥ trace cell flare ) , significant epiretinal membrane ( cause distortion macular anatomy and/or opacification ) , significant vitreomacular traction ( cause distortion macular anatomy ) , macular hole vitreous hemorrhage . Aphakia absence posterior capsule . Absence intact posterior capsule allow occur result YAG laser posterior capsulotomy association prior posterior chamber IOL implantation . History idiopathic autoimmuneassociated uveitis either eye . Significant medium opacity , include cataract , might interfere visual acuity , assessment toxicity , fundus photography study eye . Subjects enter likelihood require cataract surgery study eye next 12 month . Presence cause choroidal neovascularization , include pathologic myopia ( spherical equivalent 8 diopter , axial length 25mm ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis . Any intraocular surgery thermal laser within three ( 3 ) month trial entry . Any prior thermal laser macular region , regardless indication . Any ocular periocular infection past twelve ( 12 ) week . History follow condition procedure study eye : Rhegmatogenous retinal detachment , par plana vitrectomy , filter surgery ( e.g . trabeculectomy ) , glaucoma drainage device , corneal transplant . Previous therapeutic radiation region study eye . • History disease , metabolic dysfunction , physical examination find clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . History evidence severe cardiac disease ( e.g. , NYHA Functional Class III IV see Appendix 17.5 ) , history clinical evidence unstable angina , acute coronary syndrome , myocardial infarction coronary artery revascularization within 6 month , ventricular tachyarrythmias require ongoing treatment . Stroke ( within 12 month trial entry ) . Any major surgical procedure within one month trial entry .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>